Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
NCT ID: NCT02921035
Last Updated: 2022-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
594 participants
OBSERVATIONAL
2016-06-30
2020-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.
NCT01108887
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
NCT01112345
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
NCT01142492
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects
NCT01128075
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
NCT02949908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Relapsing Multiple Sclerosis (RMS) group
Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
Rebif (Interferon beta-1a)
Rebif will be administered at a dose of 44 mcg, sc, tiw.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rebif (Interferon beta-1a)
Rebif will be administered at a dose of 44 mcg, sc, tiw.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects diagnosed with RMS according to the revised McDonald criteria (2010)
* Treatment naïve or subjects on other DMDs who will switch to Rebif.
* Subjects will receive 1st Rebif 44 mcg dose after signing informed consent
* Subjects willing and able to provide signed informed consent.
Exclusion Criteria
* Subjects participating in other clinical studies/trials
* Any female subject of childbearing potential who is not on contraceptives
* Subjects refusal to participate in the study.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Serono Middle East FZ LLC
INDUSTRY
Merck KGaA, Darmstadt, Germany
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merck Serono Middle East FZ-LLC
Role: STUDY_DIRECTOR
an affiliate of Merck KGaA, Darmstadt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research site
Algiers, , Algeria
Research site
Annaba, , Algeria
Research site
Blida, , Algeria
Research site
Oran, , Algeria
Research site
Sétif, , Algeria
Research site
Tizi Ouzou, , Algeria
Research site
Mendoza, , Argentina
Research site
Rosario, , Argentina
Research site
San Miguel de Tucumán, , Argentina
Research site
Manama, , Bahrain
Research site
Sofia, , Bulgaria
Research site
Al Mansurah, , Egypt
Research site
Alexandria, , Egypt
Research site 1
Cairo, , Egypt
Research site 2
Cairo, , Egypt
Research site 1
Budapest, , Hungary
Research site 2
Budapest, , Hungary
Research site 3
Budapest, , Hungary
Research site
Esztergom, , Hungary
Research site
Isfahan, , Iran
Research site
Tehran, , Iran
Research site
Kuwait City, , Kuwait
Research site 1
Beirut, , Lebanon
Research site 2
Beirut, , Lebanon
Research site
Casablanca, , Morocco
Research site
Fés, , Morocco
Research site
Marrakesh, , Morocco
Research site 1
Rabat, , Morocco
Research site 2
Rabat, , Morocco
Research site 3
Rabat, , Morocco
Research site
Gdansk, , Poland
Research site
Katowice, , Poland
Research site
Lodz, , Poland
Research site
Lublin, , Poland
Research site
Rybnik, , Poland
Research site
Warsaw, , Poland
Research site
Dammam, , Saudi Arabia
Research site
Jeddah, , Saudi Arabia
Research site
Khober, , Saudi Arabia
Research site
Riyadh, , Saudi Arabia
Research site 2
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Al-Roughani R, Zakaria M, Cupler EJ, Taha K. Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study. Front Neurol. 2023 Nov 28;14:1257455. doi: 10.3389/fneur.2023.1257455. eCollection 2023.
Related Links
Access external resources that provide additional context or updates about the study.
Trial Awareness and Transparency website
Medical Information Location Map - Med Info Contacts
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS200136_0035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.